Product Information
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE is a generic product labeled by Quagen Pharmaceuticals LLC, priced at $1.9312 per EA under NDC 70752014110. Its NADAC has been published 82 times since Mar 12, 2025.
FDA first approved this application on Mar 12, 2024. Its Orange Book therapeutic-equivalence code is AA.
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINEStrength
325; 50; 40 mg/1; mg/1; mg/1
Manufacturer
Quagen Pharmaceuticals LLCNDC
70752014110
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; BUTALBITAL; CAFFEINEApproval Type
Generic (ANDA)
FDA Application
ANDA216376FDA Approved
3/12/2024
TE Code
AA
On Market Since
8/6/2022
Pharmacological Classes
Price Statistics
The NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE has been published 82 times since Mar 12, 2025, and over the history we have for it it has declined 21.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9312 per EA |
|---|---|
| All-time high | $2.7647 (Apr 16, 2025) |
| All-time low | $1.6931 (Jun 17, 2026) |
| 52-week high | $2.3000 |
| 52-week low | $1.6931 |
| Median price | $2.2150 |
| Average price | $2.1482 |
| Largest weekly change | -13.1% (Jun 18, 2025) |
| Weeks tracked | 82 |
| Tracking since | Mar 12, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BUTALBITAL, ACETAMINOPHEN AND CAFFEINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Quagen Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Barbiturate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE, manufactured by Quagen Pharmaceuticals LLC, is $1.9312 per EA (NDC 70752014110), effective Sep 30, 2026.
How has the price of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE has declined 21.8%. It has been tracked across 82 weekly CMS publications since Mar 12, 2025.
What are the highest and lowest recorded NADAC prices for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?
Since Mar 12, 2025, the NADAC for BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE has ranged from a low of $1.6931 (Jun 17, 2026) to a high of $2.7647 (Apr 16, 2025), with a median of $2.2150 per EA.
Are there cheaper alternatives to BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE?
BUTALBITAL-ACETAMINOPHEN-CAFFEINE 50-325-40 MG CAPSULE (NDC 70752014110) is labeled by Quagen Pharmaceuticals LLC, and CMS classifies it as a generic product.